Tuesday, May 17, 2022

Bionano Genomics, Inc. (BNGO) Stock Price Climbing as Saphyr System Gains Traction

Bionano Genomics, Inc. (BNGO) stock prices were up 9.85% as of market close on April 21st, 2021, bringing the price per share up to USD$5.91. Subsequent pre-market fluctuations are seeing BNGO stock prices continue to climb, increasing by 5.74% to hit USD$6.25 shortly after the trading day began on April 22nd, 2021.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Persistence Through Pandemic

Despite the adversities presented by the global pandemic throughout 2020, BNGO managed to effectively execute their commercialization of Saphyr. They managed this by broadening the scope of systems operating in the field, as well as increasing the processing volume of samples submitted to their data services lab for the purpose of analyzing.

Increasing BNGO Footprint in Genomics Sector


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


With this progress, BNGO hopes to raise increasing awareness of their offerings in regard to structural variation analysis and optical genome mapping (OGM). The wider scope will allow the company to consolidate their foothold in the genomics industry as they gear up for a promising 2021.

Plans to Sustain Success Through 2021

Plans for 2021 include advocating for the global development of assays founded on Saphyr in the use of clinical testing. The company also hopes to push for the implementation of Saphyr for use in sizeable clinical studies that aim to obtain critical masses of data on the application of Saphyr across a multitude of key structural variation analyses.

Expansive Reach of Saphyr System

The data collected is expected to facilitate the reimbursement of Saphir-based laboratory developed tests by global third party payers. The data will also drive the expansion of related publications, and see the significant growth of LDTs available on the market.

Promising Financial Records

BNGO CFO highlights the strength of the company’s balance sheet as it starts the 2021 year strong. Already, the company has generated USD$335 million in the capital which consolidates BNGO’s financial future with a significant reduction in company risk. This puts BNGO in a prime position to work towards their goal of widespread adoption of Saphyr by the global genomics industry.

Progress Made in Q1 2021

Progress on the commercialized offerings for Saphyr has been in line with the company’s strategy, with the increased generation ­of BNGO data being generated the world over driving scientific momentum. The company saw 24 base installations of Saphyr systems as of the year ended December 30th, 2020, with that number having surged to 97 over the course of 2021 already.

Investors Hopeful for Bright Future

With strong financials backing them, BNGO is set to capitalize on the progressive expansion of its Saphyr system’s user base. Investors are hopeful for sustained growth in installations that will drive the company towards increased shareholder value.

Latest news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

Related news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam